CA2913872C - A laglidadg homing endonuclease cleaving the t-cell receptor alpha gene and uses thereof - Google Patents
A laglidadg homing endonuclease cleaving the t-cell receptor alpha gene and uses thereof Download PDFInfo
- Publication number
- CA2913872C CA2913872C CA2913872A CA2913872A CA2913872C CA 2913872 C CA2913872 C CA 2913872C CA 2913872 A CA2913872 A CA 2913872A CA 2913872 A CA2913872 A CA 2913872A CA 2913872 C CA2913872 C CA 2913872C
- Authority
- CA
- Canada
- Prior art keywords
- seq
- variant
- sequence
- cells
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010042407 Endonucleases Proteins 0.000 title claims abstract description 125
- 102000004533 Endonucleases Human genes 0.000 title abstract description 29
- 108091008874 T cell receptors Proteins 0.000 title description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title description 3
- 101150087698 alpha gene Proteins 0.000 title description 2
- 239000013598 vector Substances 0.000 claims abstract description 57
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 20
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 20
- 239000002157 polynucleotide Substances 0.000 claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims description 169
- 108090000623 proteins and genes Proteins 0.000 claims description 119
- 102100031780 Endonuclease Human genes 0.000 claims description 94
- 150000007523 nucleic acids Chemical group 0.000 claims description 88
- 102000004169 proteins and genes Human genes 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 64
- 230000000694 effects Effects 0.000 claims description 61
- 102000039446 nucleic acids Human genes 0.000 claims description 55
- 108020004707 nucleic acids Proteins 0.000 claims description 55
- 230000007017 scission Effects 0.000 claims description 46
- 238000003776 cleavage reaction Methods 0.000 claims description 45
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 42
- 101710163270 Nuclease Proteins 0.000 claims description 35
- 108060002716 Exonuclease Proteins 0.000 claims description 33
- 102000013165 exonuclease Human genes 0.000 claims description 33
- 239000011159 matrix material Substances 0.000 claims description 30
- 230000003197 catalytic effect Effects 0.000 claims description 23
- 108020001580 protein domains Proteins 0.000 claims description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 238000006467 substitution reaction Methods 0.000 claims description 17
- 238000000338 in vitro Methods 0.000 claims description 13
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 claims description 10
- 108700019146 Transgenes Proteins 0.000 claims description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 10
- 229910052725 zinc Inorganic materials 0.000 claims description 10
- 239000011701 zinc Substances 0.000 claims description 10
- 108091007494 Nucleic acid- binding domains Proteins 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 102100034343 Integrase Human genes 0.000 claims description 5
- 108060004795 Methyltransferase Proteins 0.000 claims description 5
- 108091006047 fluorescent proteins Proteins 0.000 claims description 5
- 102000034287 fluorescent proteins Human genes 0.000 claims description 5
- 108010061833 Integrases Proteins 0.000 claims description 4
- 102000003960 Ligases Human genes 0.000 claims description 3
- 108090000364 Ligases Proteins 0.000 claims description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 3
- 108091000080 Phosphotransferase Proteins 0.000 claims description 3
- 102000018120 Recombinases Human genes 0.000 claims description 3
- 108010091086 Recombinases Proteins 0.000 claims description 3
- 101710183280 Topoisomerase Proteins 0.000 claims description 3
- 102000008579 Transposases Human genes 0.000 claims description 3
- 108010020764 Transposases Proteins 0.000 claims description 3
- 102000020233 phosphotransferase Human genes 0.000 claims description 3
- 101000634853 Homo sapiens T cell receptor alpha chain constant Proteins 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 abstract description 36
- 108700042076 T-Cell Receptor alpha Genes Proteins 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 230000000415 inactivating effect Effects 0.000 abstract 1
- 102000053602 DNA Human genes 0.000 description 106
- 108020004414 DNA Proteins 0.000 description 106
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 61
- 235000018102 proteins Nutrition 0.000 description 61
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 42
- 210000001744 T-lymphocyte Anatomy 0.000 description 41
- 230000014509 gene expression Effects 0.000 description 37
- 238000005520 cutting process Methods 0.000 description 36
- 102000004196 processed proteins & peptides Human genes 0.000 description 29
- 230000000670 limiting effect Effects 0.000 description 25
- 229920001184 polypeptide Polymers 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 23
- 102000004190 Enzymes Human genes 0.000 description 21
- 108090000790 Enzymes Proteins 0.000 description 21
- 229940024606 amino acid Drugs 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 21
- 230000008685 targeting Effects 0.000 description 21
- 238000002744 homologous recombination Methods 0.000 description 20
- 230000006801 homologous recombination Effects 0.000 description 20
- 108020004999 messenger RNA Proteins 0.000 description 19
- 125000003729 nucleotide group Chemical group 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 17
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 16
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 16
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 16
- 102000037865 fusion proteins Human genes 0.000 description 16
- 108020001507 fusion proteins Proteins 0.000 description 16
- 230000006780 non-homologous end joining Effects 0.000 description 16
- 239000000758 substrate Substances 0.000 description 15
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 14
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 14
- 229920002477 rna polymer Polymers 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 13
- 231100000350 mutagenesis Toxicity 0.000 description 13
- 230000035772 mutation Effects 0.000 description 13
- 210000000130 stem cell Anatomy 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 238000000684 flow cytometry Methods 0.000 description 12
- 238000010362 genome editing Methods 0.000 description 12
- 238000002703 mutagenesis Methods 0.000 description 12
- 101000634835 Homo sapiens M1-specific T cell receptor alpha chain Proteins 0.000 description 11
- 101000634836 Homo sapiens T cell receptor alpha chain MC.7.G5 Proteins 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 230000005782 double-strand break Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 230000004927 fusion Effects 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 230000004568 DNA-binding Effects 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 235000009697 arginine Nutrition 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000004520 electroporation Methods 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 239000004475 Arginine Substances 0.000 description 9
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 9
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 235000018977 lysine Nutrition 0.000 description 9
- 239000004472 Lysine Substances 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 208000036142 Viral infection Diseases 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 108091005948 blue fluorescent proteins Proteins 0.000 description 8
- 210000001161 mammalian embryo Anatomy 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000008439 repair process Effects 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000009385 viral infection Effects 0.000 description 8
- 230000007018 DNA scission Effects 0.000 description 7
- 101000582254 Homo sapiens Nuclear receptor corepressor 2 Proteins 0.000 description 7
- 101000830950 Homo sapiens Three prime repair exonuclease 2 Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 108700028369 Alleles Proteins 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 102100024872 Three prime repair exonuclease 2 Human genes 0.000 description 6
- 230000002759 chromosomal effect Effects 0.000 description 6
- 238000010363 gene targeting Methods 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 230000032965 negative regulation of cell volume Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 230000009261 transgenic effect Effects 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 235000009582 asparagine Nutrition 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 238000002619 cancer immunotherapy Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 208000024908 graft versus host disease Diseases 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000003705 ribosome Anatomy 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000004960 subcellular localization Effects 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 101100508818 Mus musculus Inpp5k gene Proteins 0.000 description 4
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 4
- 101100366438 Rattus norvegicus Sphkap gene Proteins 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000005304 joining Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 239000012114 Alexa Fluor 647 Substances 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- 101000927313 Homo sapiens DNA replication ATP-dependent helicase DNA2 Proteins 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 101710185494 Zinc finger protein Proteins 0.000 description 3
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000003209 gene knockout Methods 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 238000002708 random mutagenesis Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108010068698 spleen exonuclease Proteins 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 101100370338 Bos taurus TREX1 gene Proteins 0.000 description 2
- 108020004638 Circular DNA Proteins 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 241000283087 Equus Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 108090000652 Flap endonucleases Proteins 0.000 description 2
- 102000004150 Flap endonucleases Human genes 0.000 description 2
- 241000287826 Gallus Species 0.000 description 2
- 108091027874 Group I catalytic intron Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000830956 Homo sapiens Three-prime repair exonuclease 1 Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100370340 Mus musculus Trex1 gene Proteins 0.000 description 2
- 102000013901 Nucleoside diphosphate kinase Human genes 0.000 description 2
- 108700023477 Nucleoside diphosphate kinases Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102100024855 Three-prime repair exonuclease 1 Human genes 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 241000589634 Xanthomonas Species 0.000 description 2
- SAZUGELZHZOXHB-UHFFFAOYSA-N acecarbromal Chemical compound CCC(Br)(CC)C(=O)NC(=O)NC(C)=O SAZUGELZHZOXHB-UHFFFAOYSA-N 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 108020001778 catalytic domains Proteins 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 150000004000 hexols Chemical class 0.000 description 2
- -1 hosphatase Proteins 0.000 description 2
- 102000045960 human DNA2 Human genes 0.000 description 2
- 102000054586 human TREX2 Human genes 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000002894 multi-fate stem cell Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 244000000003 plant pathogen Species 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 210000004986 primary T-cell Anatomy 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000003007 single stranded DNA break Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 108010036169 three prime repair exonuclease 1 Proteins 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000003014 totipotent stem cell Anatomy 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 241000710189 Aphthovirus Species 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101001137540 Bos taurus Endonuclease G, mitochondrial Proteins 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 241000244202 Caenorhabditis Species 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 101100491149 Caenorhabditis elegans lem-3 gene Proteins 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108091060290 Chromatid Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 101710159064 Colicin-E7 Proteins 0.000 description 1
- 108010073254 Colicins Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 230000007064 DNA hydrolysis Effects 0.000 description 1
- 102100033072 DNA replication ATP-dependent helicase DNA2 Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 101710134695 Endodeoxyribonuclease 1 Proteins 0.000 description 1
- 101710204468 Endonuclease YncB Proteins 0.000 description 1
- 102000002241 Eukaryotic Initiation Factors Human genes 0.000 description 1
- 108010014863 Eukaryotic Initiation Factors Proteins 0.000 description 1
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 240000005702 Galium aparine Species 0.000 description 1
- 235000014820 Galium aparine Nutrition 0.000 description 1
- 241000941423 Grom virus Species 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001137538 Homo sapiens Endonuclease G, mitochondrial Proteins 0.000 description 1
- 101000979629 Homo sapiens Nucleoside diphosphate kinase A Proteins 0.000 description 1
- 101000836339 Homo sapiens Transposon Hsmar1 transposase Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108010059343 MM Form Creatine Kinase Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000288145 Meleagris Species 0.000 description 1
- 241000288147 Meleagris gallopavo Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 101150101095 Mmp12 gene Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102100023252 Nucleoside diphosphate kinase A Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000277334 Oncorhynchus Species 0.000 description 1
- 241000277275 Oncorhynchus mykiss Species 0.000 description 1
- 241000221871 Ophiostoma Species 0.000 description 1
- 241000144580 Ophiostoma novo-ulmi Species 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 108700001094 Plant Genes Proteins 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000232299 Ralstonia Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 101100404456 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YNK1 gene Proteins 0.000 description 1
- 241000277263 Salmo Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 101000965899 Simian virus 40 Large T antigen Proteins 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 108700039575 Three prime repair exonuclease 2 Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102100027172 Transposon Hsmar1 transposase Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 150000001484 arginines Chemical class 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000004668 avian leukosis Diseases 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008970 bacterial immunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 210000004756 chromatid Anatomy 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 108010057988 ecdysone receptor Proteins 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002616 endonucleolytic effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000001036 exonucleolytic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 108010055863 gene b exonuclease Proteins 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 102000005396 glutamine synthetase Human genes 0.000 description 1
- 108020002326 glutamine synthetase Proteins 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 108010002685 hygromycin-B kinase Proteins 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000021005 inheritance pattern Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000000415 mammalian chromosome Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 101150071637 mre11 gene Proteins 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 101150054576 ndk1 gene Proteins 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004492 nuclear pore Anatomy 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 108010085336 phosphoribosyl-AMP cyclohydrolase Proteins 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108010033804 ribosomal protein S3 Proteins 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 101150013092 rps3 gene Proteins 0.000 description 1
- 102220278926 rs759871071 Human genes 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201370303 | 2013-05-31 | ||
| DKPA201370303 | 2013-05-31 | ||
| PCT/EP2014/061189 WO2014191527A1 (en) | 2013-05-31 | 2014-05-28 | A laglidadg homing endonuclease cleaving the t cell receptor alpha gene and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2913872A1 CA2913872A1 (en) | 2014-12-04 |
| CA2913872C true CA2913872C (en) | 2022-01-18 |
Family
ID=48628226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2913872A Active CA2913872C (en) | 2013-05-31 | 2014-05-28 | A laglidadg homing endonuclease cleaving the t-cell receptor alpha gene and uses thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10000746B2 (OSRAM) |
| EP (1) | EP3004338B1 (OSRAM) |
| JP (1) | JP6450371B2 (OSRAM) |
| AU (1) | AU2014273091B2 (OSRAM) |
| CA (1) | CA2913872C (OSRAM) |
| DK (1) | DK3004338T3 (OSRAM) |
| ES (1) | ES2716867T3 (OSRAM) |
| WO (1) | WO2014191527A1 (OSRAM) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5996630B2 (ja) * | 2011-04-05 | 2016-09-21 | セレクティスＣｅｌｌｅｃｔｉｓ | コンパクトｔａｌｅ−ヌクレアーゼを作製する方法及びその使用 |
| JP6261500B2 (ja) | 2011-07-22 | 2018-01-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ヌクレアーゼ切断特異性の評価および改善 |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| PT3066201T (pt) | 2013-11-07 | 2018-06-04 | Massachusetts Inst Technology | Métodos e composições relacionadas com crispr com arng reguladores |
| US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| JP6816133B2 (ja) | 2015-10-05 | 2021-01-20 | プレシジョン バイオサイエンシズ，インク． | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
| US10799535B2 (en) | 2015-10-05 | 2020-10-13 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene |
| EP3365356B1 (en) | 2015-10-23 | 2023-06-28 | President and Fellows of Harvard College | Nucleobase editors and uses thereof |
| SG10202109655VA (en) | 2015-12-04 | 2021-10-28 | Novartis Ag | Compositions and methods for immunooncology |
| EP3426690A4 (en) * | 2016-03-11 | 2019-10-09 | Bluebird Bio, Inc. | GENOMEDITIZED IMMUNEFFECTOR CELLS |
| EP4166161A1 (en) * | 2016-04-14 | 2023-04-19 | Fred Hutchinson Cancer Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| US10188749B2 (en) | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| CA3031785A1 (en) * | 2016-07-25 | 2018-02-01 | Bluebird Bio, Inc. | Bcl11a homing endonuclease variants, compositions, and methods of use |
| JP7231935B2 (ja) | 2016-08-03 | 2023-03-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | アデノシン核酸塩基編集因子およびそれらの使用 |
| EP3497214B1 (en) | 2016-08-09 | 2023-06-28 | President and Fellows of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| EP3500696A4 (en) * | 2016-08-16 | 2020-04-08 | Bluebird Bio, Inc. | VARIANTS OF IL-10 ALPHA RECEPTOR HOMING ENDONUCLEASE, COMPOSITIONS AND METHODS OF USE |
| WO2018039333A1 (en) * | 2016-08-23 | 2018-03-01 | Bluebird Bio, Inc. | Tim3 homing endonuclease variants, compositions, and methods of use |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| KR102622910B1 (ko) * | 2016-09-08 | 2024-01-10 | 2세븐티 바이오, 인코포레이티드 | Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법 |
| US11591582B2 (en) | 2016-10-11 | 2023-02-28 | 2Seventy Bio, Inc. | TCRα homing endonuclease variants |
| EP3526320A1 (en) | 2016-10-14 | 2019-08-21 | President and Fellows of Harvard College | Aav delivery of nucleobase editors |
| WO2018075541A1 (en) * | 2016-10-17 | 2018-04-26 | Bluebird Bio, Inc. | TGFβR2 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| BR112019011277A2 (pt) | 2016-12-02 | 2019-10-22 | University Of Southern California | polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos. |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| EP3565535A4 (en) | 2017-01-05 | 2020-12-30 | Fred Hutchinson Cancer Research Center | SYSTEMS AND METHODS FOR IMPROVING THE EFFECTIVENESS OF A VACCINE |
| WO2018165631A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Cancer vaccine |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| KR20190127797A (ko) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 시토신에서 구아닌으로의 염기 편집제 |
| JP2020513832A (ja) | 2017-03-22 | 2020-05-21 | ノバルティス アーゲー | 免疫腫瘍学のための組成物および方法 |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| EP3592854A1 (en) | 2017-04-13 | 2020-01-15 | Cellectis | New sequence specific reagents targeting ccr5 in primary hematopoietic cells |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| MA48797A (fr) | 2017-05-25 | 2020-04-08 | Bluebird Bio Inc | Variants de l'endonucléase cblb , compositions et procédés d'utilisation |
| US11053484B2 (en) | 2017-06-30 | 2021-07-06 | Precision Biosciences, Inc. | Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene |
| WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| WO2019070974A1 (en) * | 2017-10-04 | 2019-04-11 | Bluebird Bio, Inc. | PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE |
| JP7207661B2 (ja) * | 2017-10-10 | 2023-01-18 | 国立大学法人広島大学 | Ｐｌａｔｉｎｕｍ ＴＡＬＥＮを用いたＴ細胞受容体の完全置換技術 |
| WO2019073965A1 (ja) | 2017-10-10 | 2019-04-18 | 国立大学法人広島大学 | エフェクターＴ細胞（Ｔｅｆｆ）抗原受容体を用いた抗原特異的制御性Ｔ細胞（Ｔｒｅｇ）の作出技術 |
| CN111757937A (zh) | 2017-10-16 | 2020-10-09 | 布罗德研究所股份有限公司 | 腺苷碱基编辑器的用途 |
| BR112020009889A2 (pt) | 2017-12-14 | 2020-11-03 | Flodesign Sonics, Inc. | acionador e controlador de transdutor acústico |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| WO2019126555A1 (en) * | 2017-12-20 | 2019-06-27 | Bluebird Bio, Inc. | Ctla4 homing endonuclease variants, compositions, and methods of use |
| IL304025A (en) | 2018-04-12 | 2023-08-01 | Prec Biosciences Inc | Optimized engineered nucleases with specificity for the human T cell receptor alpha constant region gene |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| EP3806903B1 (en) | 2018-06-14 | 2024-02-14 | 2seventy bio, Inc. | Cd79a chimeric antigen receptors |
| WO2020072059A1 (en) | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| KR20210102925A (ko) | 2018-12-10 | 2021-08-20 | 블루버드 바이오, 인코포레이티드. | 호밍 엔도뉴클레아제 변이체 |
| WO2020154500A1 (en) | 2019-01-23 | 2020-07-30 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| MX2021011426A (es) | 2019-03-19 | 2022-03-11 | Broad Inst Inc | Metodos y composiciones para editar secuencias de nucleótidos. |
| CN116200342A (zh) | 2019-04-03 | 2023-06-02 | 精密生物科学公司 | 包含microRNA适应的shRNA（shRNAmiR）的遗传修饰的免疫细胞 |
| EP3956349A1 (en) | 2019-04-17 | 2022-02-23 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2021016608A1 (en) | 2019-07-25 | 2021-01-28 | Precision Biosciences, Inc. | Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus |
| EP4017526A1 (en) | 2019-08-20 | 2022-06-29 | Precision BioSciences, Inc. | Lymphodepletion dosing regimens for cellular immunotherapies |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| WO2021087305A1 (en) | 2019-10-30 | 2021-05-06 | Precision Biosciences, Inc. | Cd20 chimeric antigen receptors and methods of use for immunotherapy |
| MX2022014008A (es) | 2020-05-08 | 2023-02-09 | Broad Inst Inc | Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo. |
| WO2022035793A1 (en) | 2020-08-10 | 2022-02-17 | Precision Biosciences, Inc. | Antibodies and fragments specific for b-cell maturation antigen and uses thereof |
| US20240336904A1 (en) * | 2020-12-21 | 2024-10-10 | 2Seventy Bio, Inc. | Compositions and methods for site-directed mutagenesis |
| WO2022165111A1 (en) | 2021-01-28 | 2022-08-04 | Precision Biosciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
| EP4426832A1 (en) | 2021-11-03 | 2024-09-11 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Precise genome editing using retrons |
| WO2023081767A1 (en) | 2021-11-05 | 2023-05-11 | Precision Biosciences, Inc. | Methods for immunotherapy |
| MX2024006051A (es) | 2021-11-23 | 2024-06-26 | Cellectis Sa | Nuevos andamios de proteinas tale con relaciones de actividad en objetivo/fuera de objetivo mejoradas. |
| WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| WO2024044723A1 (en) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| AU2024206812A1 (en) | 2023-01-05 | 2025-08-14 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8956828B2 (en) * | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| US20140148361A1 (en) | 2010-06-07 | 2014-05-29 | Barry L. Stoddard | Generation and Expression of Engineered I-ONUI Endonuclease and Its Homologues and Uses Thereof |
| JP5996630B2 (ja) * | 2011-04-05 | 2016-09-21 | セレクティスＣｅｌｌｅｃｔｉｓ | コンパクトｔａｌｅ−ヌクレアーゼを作製する方法及びその使用 |
| WO2013009525A1 (en) * | 2011-07-08 | 2013-01-17 | Cellectis S.A. | Method for increasing the efficiency of double-strand break-induced mutagenssis |
| US20130210151A1 (en) * | 2011-11-07 | 2013-08-15 | University Of Western Ontario | Endonuclease for genome editing |
-
2014
- 2014-05-28 US US14/891,216 patent/US10000746B2/en active Active
- 2014-05-28 JP JP2016516173A patent/JP6450371B2/ja active Active
- 2014-05-28 DK DK14728899.7T patent/DK3004338T3/en active
- 2014-05-28 CA CA2913872A patent/CA2913872C/en active Active
- 2014-05-28 ES ES14728899T patent/ES2716867T3/es active Active
- 2014-05-28 AU AU2014273091A patent/AU2014273091B2/en active Active
- 2014-05-28 WO PCT/EP2014/061189 patent/WO2014191527A1/en not_active Ceased
- 2014-05-28 EP EP14728899.7A patent/EP3004338B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3004338A1 (en) | 2016-04-13 |
| US10000746B2 (en) | 2018-06-19 |
| US20160130569A1 (en) | 2016-05-12 |
| JP6450371B2 (ja) | 2019-01-09 |
| CA2913872A1 (en) | 2014-12-04 |
| ES2716867T3 (es) | 2019-06-17 |
| HK1223394A1 (en) | 2017-07-28 |
| JP2016520320A (ja) | 2016-07-14 |
| AU2014273091A1 (en) | 2015-12-03 |
| AU2014273091B2 (en) | 2019-12-12 |
| EP3004338B1 (en) | 2019-01-02 |
| DK3004338T3 (en) | 2019-04-08 |
| WO2014191527A1 (en) | 2014-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2913872C (en) | A laglidadg homing endonuclease cleaving the t-cell receptor alpha gene and uses thereof | |
| EP3004149B1 (en) | A laglidadg homing endonuclease cleaving the c-c chemokine receptor type-5 (ccr5) gene and uses thereof | |
| CN102264915B (zh) | 失活谷氨酰胺合成酶基因表达的方法和组合物 | |
| WO2020041249A1 (en) | Engineered target specific base editors | |
| IL202555A (en) | Mega-nuclease variants for hatching a DNA target sequence from a 26 rosa mouse and their uses | |
| WO2012058458A2 (en) | Method for increasing the efficiency of double-strand break-induced mutagenesis | |
| US20220162648A1 (en) | Compositions and methods for improved gene editing | |
| US20130189759A1 (en) | Meganucleases variants cleaving a dna target sequence in the nanog gene and uses thereof | |
| JP2024532784A (ja) | 新規なｏｍｎｉ－１１５、１２４、１２７、１４４～１４９、１５９、２１８、２３７、２４８、２５１～２５３及び２５９ｃｒｉｓｐｒヌクレアーゼ | |
| Jang et al. | Genome editing systems in novel therapies | |
| HK1223394B (en) | A laglidadg homing endonuclease cleaving the t cell receptor alpha gene and uses thereof | |
| HK1223373B (en) | A laglidadg homing endonuclease cleaving the c-c chemokine receptor type-5 (ccr5) gene and uses thereof | |
| WO2012007848A2 (en) | Meganuclease variants cleaving a dna target sequence in the was gene and uses thereof | |
| US20160138047A1 (en) | Improved polynucleotide sequences encoding tale repeats | |
| Class et al. | Patent application title: A LAGLIDADG HOMING ENDONUCLEASE CLEAVING THE T CELL RECEPTOR ALPHA GENE AND USES THEREOF Inventors: Jordan Jarjour (Seattle, WA, US) Alexander Astrakhan (Seattle, WA, US) | |
| Checketts | Nuclease-Mediated Targeted Gene Insertion at the Adenosine Deaminase Locus in Primary Cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190528 |